Poxel Holds Combined General Meeting, Announces Key Results

Poxel SA, a clinical stage biopharmaceutical company based in Lyon, France, held its Combined General Meeting on February 11, 2025. The meeting was attended by shareholders holding a total of 18,380,495 voting rights, forming a 34.26% quorum. Key resolutions included the approval of the revised remuneration policy for corporate officers as proposed by the Board of Directors.

Notably, the meeting did not adopt certain financial delegations, specifically affecting the IRIS program. This non-adoption could trigger an event of default under the ORANE and IPF Partners bonds, allowing for immediate redemption requests. The Board, alongside company management, will assess implications and communicate further with creditors and stakeholders.

Poxel's next financial update, focusing on its fourth quarter 2024 cash and revenue, is scheduled for February 19, 2025.